Top

Published in:

01-07-2021 | Fracture Healing | Original Research

Phenanthrenoid Coelogin Isolated from Coelogyne cristata Exerts Osteoprotective Effect Through MAPK-Mitogen-Activated Protein Kinase Signaling Pathway

Authors: Ravi Prakash, Tripti Mishra, Kapil Dev, Kriti Sharma, Jitendra Kuldeep, Aijaz Ahmad John, Alok Tripathi, Chetan Sharma, Kamal Ram Arya, Brijesh Kumar, Mohd Imran Siddiqi, Narender Tadigoppula, Divya Singh

Published in: Calcified Tissue International | Issue 1/2021

Abstract

Osteoporosis is a major health problem in postmenopausal women globally. This study determined the mechanism through which coelogin stimulates osteoblastogenesis and its osteoprotective and bone regenerating potential. Coelogin effect on primary calvarial osteoblast cells was determined by measuring alkaline phosphatase activity, mineralization, osteoblast survival, and apoptosis and protein expression studies. The osteoprotective effect of coelogin was also evaluated on osteopenic adult female Swiss mice. At autopsy, bones were collected for dynamic and histomorphometry studies. Serum samples were also collected for assessment of serum parameters. Coelogin treatment led to increased osteoblast proliferation, survival, differentiation, and mineralization in osteoblast cells. Coelogin supplementation to Ovx mice promoted new bone formation, prevented Ovx-induced deterioration of bone microarchitecture, and enhanced bone regeneration. In addition, signaling studies revealed that coelogin treatment activates the ER-Erk and Akt-dependent signaling pathways which stimulate the osteoblastogenesis in osteoblast cells.

Available only for authorised users

Garnero P, Delmas PD (2004) Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact 4(1):50PubMed

Tabacco G, Tay YD, Cusano NE, Williams J, Omeragic B, Majeed R, Almonte MG, Rubin MR, Bilezikian JP (2019) Quality of life in hypoparathyroidism improves with rhPTH(1–84) throughout 8 years of therapy. J Clin Endocrinol Metab 104:2748–2756. https://doi.org/10.1210/jc.2018-02430CrossRefPubMedPubMedCentral

Noel SE, Mangano KM, Griffith JL, Wright NC, Dawson-Hughes B, Tucker KL (2018) Prevalence of osteoporosis and low bone mass among Puerto Rican older adults. J Bone Miner Res 33(3):396–403. https://doi.org/10.1002/jbmr.3315CrossRefPubMed

Reid IR (2008) Anti-resorptive therapies for osteoporosis. Seminars in cell & developmental biology, vol 19. Academic Press, Cambridge, pp 473–478

Deal C (2009) Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol 5:20–27. https://doi.org/10.1038/ncprheum0977CrossRefPubMed

Anagnostis P, Gkekas NK, Potoupnis M, Kenanidis E, Tsiridis E, Goulis DG (2019) New therapeutic targets for osteoporosis. Maturitas 120:1–6CrossRef

Wojda SJ, Donahue SW (2018) Parathyroid hormone for bone regeneration. J Orthop Res 36(10):2586–2594CrossRef

Wein MN, Kronenberg HM (2018) Regulation of bone remodeling by parathyroid hormone. Cold Spring Harb Perspect Med 8(8):a031237CrossRef

Dobnig H, Turner RT (1995) Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136:3632–3638. https://doi.org/10.1210/endo.136.8.7628403CrossRefPubMed

10.

Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC (1999) Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439–446. https://doi.org/10.1172/JCI6610CrossRefPubMedPubMedCentral

11.

Sen S, Chakraborty R (2017) Revival, modernization and integration of Indian traditional herbal medicine in clinical practice: importance, challenges and future. J Tradit Complement Med 7(2):234–244CrossRef

12.

Sharma C, Mansoori MN, Dixit M, Shukla P, Kumari T, Bhandari SP, Narender T, Singh D, Arya KR (2014) Ethanolic extract of Coelogyne cristata Lindley (Orchidaceae) and its compound coelogin promote osteoprotective activity in ovariectomized estrogen deficient mice. Phytomedicine 21:1702–1707. https://doi.org/10.1016/j.phymed.2014.08.008CrossRefPubMed

13.

Tripathi JK, Pal S, Awasthi B, Kumar A, Tandon A, Mitra K, Chattopadhyay C, Ghosh JK (2015) Variants of self-assembling peptide, KLD-12 that show both rapid fracture healing and antimicrobial properties. Biomaterials 56:92–103. https://doi.org/10.1016/j.biomaterials.2015.03.046CrossRefPubMed

14.

Pal KK, China SP, Mittal M, Shrivastava R, Taneja I, Hossain Z, Mandalapu D, Gayen JR, Wahajuddin M, Sharma VL (2016) Theophylline, a methylxanthine drug induces osteopenia and alters calciotropic hormones, and prophylactic vitamin D treatment protects against these changes in rats. Toxicol Appl Pharmacol 295:12–25. https://doi.org/10.1016/J.TAAP.2016.02.002CrossRefPubMed

15.

Bhargavan B, Gautam AK, Singh D, Kumar A, Chaurasia S, Tyagi AM, Yadav DK, Mishra JS, SinghAB SS, Goel A (2009) Methoxylated isoflavones, cajanin and isoformononetin, have non-estrogenic bone forming effect via differential mitogen activated protein kinase (MAPK) signaling. J Cell Biochem 108:388–399. https://doi.org/10.1002/jcb.22264CrossRefPubMed

16.

Adhikary S, Choudhary D, Ahmad N, Karvande A, Kumar A, Banala VT, Mishra PR, Trivedi R (2018) Dietary flavonoid kaempferol inhibits glucocorticoid-induced bone loss by promoting osteoblast survival. Nutrition 53:64–76. https://doi.org/10.1016/j.nut.2017.12.003CrossRefPubMed

17.

Meleti Z, Shapiro IM, Adams CS (2000) Inorganic phosphate induces apoptosis of osteoblast-like cells in culture. Bone 27:359–366. https://doi.org/10.1016/S8756-3282(00)00346-XCrossRefPubMed

18.

Jia TL, Wang HZ, Xie LP, Wang XY, Zhang RQ (2003) Daidzein enhances osteoblast growth that may be mediated by increased bone morphogenetic protein (BMP) production. Biochem Pharmacol 65:709–715. https://doi.org/10.1016/S0006-2952(02)01585-XCrossRefPubMed

19.

Nakamura H, Kumei Y, Morita S, Shimokawa H, Ohya K, Shinomiya K (2003) Antagonism between apoptotic (Bax/Bcl-2) and anti-apoptotic (IAP) signals in human osteoblastic cells under vector-averaged gravity condition. Ann N Y Acad Sci 1010:143–147. https://doi.org/10.1196/annals.1299.023CrossRefPubMed

20.

Nagase Y, Iwasawa M, Akiyama T, KadonoY NM, Oshima Y, Yasui T, Matsumoto T, Hirose J, Nakamura H, Miyamoto T (2009) Anti-apoptotic molecule Bcl-2 regulates the differentiation, activation, and survival of both osteoblasts and osteoclasts. J Biol Chem 284:36659–36669. https://doi.org/10.1074/jbc.M109.016915CrossRefPubMedPubMedCentral

21.

Calderone L, Grimes P, Shalev M (1986) Acute reversible cataract induced by xylazine and by ketamine-xylazine anesthesia in rats and mice. Exp Eye Res 42:331–337. https://doi.org/10.1016/0014-4835(86)90026-6CrossRefPubMed

22.

Hara K, Kobayashi M, Akiyama Y (2002) Vitamin K2 (menatetrenone) inhibits bone loss induced by prednisolone partly through enhancement of bone formation in rats. Bone 31:575–581. https://doi.org/10.1016/S8756-3282(02)00874-8CrossRefPubMed

23.

Chen HL, Demiralp B, Schneider A, Koh AJ, Silve C, Wang CY, McCauley LK (2002) Parathyroid hormone and parathyroid hormone-related protein exert both pro- and anti-apoptotic effects in mesenchymal cells. J Biol Chem 277:19374–19381. https://doi.org/10.1074/jbc.m108913200CrossRefPubMed

24.

Chau JF, Leong WF, Li B (2009) Signaling pathways governing osteoblast proliferation, differentiation and function. Histol Histopathol 24:1593–1606. https://doi.org/10.14670/hh-24.1593CrossRefPubMed

25.

Yang XS, Liu S, Liu YJ, Liu JW, Liu TJ, Wang XQ, Yan Q (2010) Overexpression of fucosyltransferase IV promotes A431 cell proliferation through activating MAPK and PI3K/Akt signaling pathways. J Cell Physiol 225:612–619. https://doi.org/10.1002/jcp.22250CrossRefPubMed

26.

He YX, Zhang G, Pan XH, Liu Z, Zheng LZ, Chan CW, Lee KM, Cao YP, Li G, Wei L, Hung LK (2011) Impaired bone healing pattern in mice with ovariectomy-induced osteoporosis: a drill-hole defect model. Bone 48:1388–1400. https://doi.org/10.1016/j.bone.2011.03.720CrossRefPubMed

27.

Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD (2013) Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int 24:489–494. https://doi.org/10.1007/s00198-012-1978-xCrossRefPubMed

28.

He YX, Liu Z, Pan XH, Tang T, Guo BS, Zheng LZ, Xie XH, Wang XL, Lee KM, Li G, Cao YP (2012) Deletion of estrogen receptor beta accelerates early stage of bone healing in a mouse osteotomy model. Osteoporos Int 23:377–389. https://doi.org/10.1007/s00198-011-1812-xCrossRefPubMed

29.

Khan K, Sharan K, Swarnkar G, Chakravarti B, Mittal M, Barbhuyan TK, China SP, Khan MP, Nagar GK, Yadav D, Dixit P (2013) Positive skeletal effects of cladrin, a naturally occurring dimethoxydaidzein, in osteopenic rats that were maintained after treatment discontinuation. Osteoporos Int 24:1455–1470. https://doi.org/10.1007/s00198-012-2121-8CrossRefPubMed

Title: Phenanthrenoid Coelogin Isolated from Coelogyne cristata Exerts Osteoprotective Effect Through MAPK-Mitogen-Activated Protein Kinase Signaling Pathway
Authors: Ravi Prakash
Tripti Mishra
Kapil Dev
Kriti Sharma
Jitendra Kuldeep
Aijaz Ahmad John
Alok Tripathi
Chetan Sharma
Kamal Ram Arya
Brijesh Kumar
Mohd Imran Siddiqi
Narender Tadigoppula
Divya Singh
Publication date: 01-07-2021
Publisher: Springer US
Keywords: Fracture Healing
Osteoporosis
Osteoporosis
Published in: Calcified Tissue International / Issue 1/2021
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-021-00818-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Silencing Proteasome 26S Subunit ATPase 2 (PSMC2) Protects the Osteogenic Differentiation In Vitro and Osteogenesis In Vivo

Correction to: Targeted Inactivation of Rin3 Increases Trabecular Bone Mass by Reducing Bone Resorption and Favouring Bone Formation

Identification of Novel Pleiotropic SNPs Associated with Osteoporosis and Rheumatoid Arthritis

Sclerostin Directly Stimulates Osteocyte Synthesis of Fibroblast Growth Factor-23

Targeted Inactivation of Rin3 Increases Trabecular Bone Mass by Reducing Bone Resorption and Favouring Bone Formation

Effect of Zoledronate on Lower Respiratory Infections in Older Women: Secondary Analysis of a Randomized Controlled Trial

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials